<DOC>
	<DOCNO>NCT02315326</DOCNO>
	<brief_summary>The purpose study test good bad effect study drug call ibrutinib ( also know Imbruvica™ ) 840mg daily dose patient lymphoma central nervous system .</brief_summary>
	<brief_title>Bruton 's Tyrosine Kinase ( BTK ) Inhibitor , Ibrutinib , Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma ( PCNSL ) Refractory/Recurrent Secondary Central Nervous System Lymphoma ( SCNSL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neurologic Manifestations</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>The population consist adult patient relapse refractory primary central nervous system lymphoma ( PCNSL ) relapse refractory secondary central nervous system lymphoma ( SCNSL ) Patients eligible inclusion study meet follow criterion : Participants must able understand willing sign write informed consent document Men woman least 18 year age day consent study Histologically document PCNSL histologically document systemic diffuse large Bcell lymphoma ( DLBCL ) Patients must relapsed/refractory PCNSL relapsed/refractory SCNSL All patient need receive least one prior CNS direct therapy . There restriction number recurrence Patients parenchymal lesion must unequivocal evidence disease progression imaging ( MRI brain head CT ) 21 day prior study registration . For patient leptomeningeal disease , CSF cytology must document lymphoma cell and/or image finding consistent CSF disease 21 day prior study registration ( discretion investigator ) Participants must ECOG performance status 0 , 1 , 2 Participants must adequate bone marrow organ function show : Absolute neutrophil count ( ANC ) ≥ 0.75 x 109/L Platelets ≥ 75 x 109/L platelet transfusion within past 21 day prior study registration Hemoglobin ( Hgb ) ≥ 8 g/dL red blood cell ( RBC ) transfusion within past 21 day prior study registration International Normalized Ratio ( INR ) ≤ 1.5 PTT ( aPTT ) ≤ 1.5 time upper limit normal Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 time upper limit normal Serum bilirubin ≤ 1.5 time upper limit normal ; total bilirubin ≤ 3 time upper limit normal direct bilirubin within normal range patient well document Gilbert Syndrome Serum creatinine ≤ 2 time upper limit normal Arm C : calculated creatinine clearance ( CrCl ) &gt; 50ml/min use CockcroftGault equation ( Men : CrCl ( min/ml ) = ( 140age ) X ( actual weight kg ) / 72 X serum creatinine ( mg/dL ) ; Women : CrCl ( ml/min ) = ( 140age ) X ( actual weight kg ) X 0.85 / 72 X serum creatinine ( mg/dL ) ) Woman reproductive potential must agree use highly effective method birth control period therapy 30 day last dose study drug . Men sexually active must agree use highly effective contraception period therapy 3 month last dose Female subject childbearing potential must negative plasma pregnancy test upon study entry . See section Pregnancy Reproduction Patients must able tolerate MRI/CT scan Patients must able tolerate lumbar puncture and/or Ommaya tap Participants must recover grade 1 toxicity prior therapy Participates must able submit 20 unstained formalinfixed , paraffinembedded ( FFPE ) slide initial tissue diagnosis prior study registration confirmation diagnosis correlative study Arm C : SCNSL patient require one prior CNS direct treatment . Newly diagnose SCNSL patient eligible long systemic disease treat require active treatment . NOTE : Prior autologous stem cell transplant well prior radiation CNS NOT prevent patient enrollment trial Patients SCNSL actively receive treatment extraCNS disease exclude Patient concurrently use approve investigational antineoplastic agent Patient receive chemotherapy , monoclonal antibody target anticancer therapy ≤ 4 week 5 halflives , whichever short , 6 week nitrosurea , mitomycinC prior start study drug , patient recover side effect therapy Patient receive external beam radiation therapy CNSwithin 21 day first dose study drug Patient require 8 mg dexamethasone daily equivalent Patient active concurrent malignancy require active therapy The patient treat radio toxinimmunoconjugates within 70 day first dose study drug Patient previously take allergic component study drug . For Arms A B : Patient previously take ibrutinib . Patient use warfarin Coumadinderivative anticoagulant vitamin K antagonist . Patients must warfarinderivative anticoagulant least seven day prior start study drug . Low molecular weight heparin allow . Patients congenital bleeding diathesis exclude Patient take drug know moderate strong inhibitor inducer P450 isoenzyme CYP3A . Participants must P450/CYP3A inhibitor inducer least two week prior start study drug Patient use systemic immunosuppressant therapy , include cyclosporine A , tacrolimus , sirolimus , medication , chronic administration &gt; 5 mg/day prednisone equivalent . Participants must immunosuppressant therapy least 28 day prior first dose study drug Patient significant abnormality screen electrocardiogram ( EKG ) active significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , hypertension , valvular disease , pericarditis , myocardial infarction within 6 month screen Patient know bleed diathesis ( e.g . von Willebrand 's disease ) hemophilia Patient know human immunodeficiency virus ( HIV ) infection Patient know history active chronic infection hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) determine serologic test Patient know uncontrolled active systemic infection Patient underwent major systemic surgery ≤ 2 week prior start trial treatment recover side effect surgery , plan surgery within 2 week first dose study drug Patient unable swallow capsule disease condition significantly affect gastrointestinal function , malabsorption syndrome , resection stomach small bowel , complete bowel obstruction Patient poorly control diabetes mellitus glycosylated hemoglobin &gt; 8 % poorly control steroidinduced diabetes mellitus glycosylated hemoglobin &gt; 8 % Patient lifethreatening illness , medical condition , organ system dysfunction , opinion investigator , could compromise subject 's safety put study outcome undue risk Women pregnant nursing ( lactate ) , pregnancy define state female conception termination gestation , confirm positive serum hCG laboratory test &gt; 5 mIU/mL ( See section Pregnancy Reproduction ) Patient undergone prior allogenic stem cell transplant ( autologous stem cell transplant NOT exclusion ) The patient unwell unable participate require study evaluation procedures Patient unable understand purpose risk study provide sign date informed consent form ( ICF ) authorization use protect health information ( PHI ) accordance national local subject privacy regulation . A legal representative consent behalf patient able understand purpose risk study able provide signature ICF authorization use PHI due neurologic deficit ( e.g . motor language deficit ) Arm C : Patients methotrexate allergy exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ibrutinib ,</keyword>
	<keyword>Imbruvica™</keyword>
	<keyword>Bruton 's Tyrosine Kinase ( BTK ) Inhibitor</keyword>
	<keyword>HD-MTX</keyword>
	<keyword>14-184</keyword>
</DOC>